The state-of-the-art in chemoprevention of skin cancer

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate. Our chemoprevention strategies include the development of novel agents evaluated by (1) preclinical mechanistic studies in models of ultraviolet (UV) radiation-induced skin carcinogenesis; (2) clinical studies of immunohistochemical surrogate endpoint biomarkers in high-risk patients; and (3) randomised, placebo-controlled phase I, II and III clinical chemoprevention trials. Recent clinical results validate this development model. Molecular targets of chemopreventive strategies for melanoma and non-melanoma skin cancers include the ras and activator protein-1 (AP-1) signal transduction pathways. A transgenic murine melanoma model has been developed for evaluating potential agents in vivo. Agents at various stages of study include the green tea catechin epigallocatechin gallate (EGCG), the limonene derivative perillyl alcohol, the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO), selenium, retinoids and salicylates. New chemopreventive agents that can be used to complement sunscreens may result in decreased incidence, morbidity and mortality of skin cancer. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)1292-1297
Number of pages6
JournalEuropean Journal of Cancer
Volume36
Issue number10
DOIs
StatePublished - Jun 2000

Fingerprint

Chemoprevention
Skin Neoplasms
Melanoma
perilla alcohol
Biomarkers
Eflornithine
ras Proteins
Sunscreening Agents
Salicylates
Incidence
Transcription Factor AP-1
Retinoids
Tea
Selenium
Signal Transduction
Carcinogenesis
Placebos
Clinical Trials
Radiation
Morbidity

Keywords

  • Chemoprevention
  • Clinical trials
  • Skin neoplasms
  • Ultraviolet rays

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The state-of-the-art in chemoprevention of skin cancer. / Stratton, Steven P; Dorr, Robert T; Alberts, David S.

In: European Journal of Cancer, Vol. 36, No. 10, 06.2000, p. 1292-1297.

Research output: Contribution to journalArticle

@article{c110d28eb5a3438ab353c3486482c843,
title = "The state-of-the-art in chemoprevention of skin cancer",
abstract = "The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate. Our chemoprevention strategies include the development of novel agents evaluated by (1) preclinical mechanistic studies in models of ultraviolet (UV) radiation-induced skin carcinogenesis; (2) clinical studies of immunohistochemical surrogate endpoint biomarkers in high-risk patients; and (3) randomised, placebo-controlled phase I, II and III clinical chemoprevention trials. Recent clinical results validate this development model. Molecular targets of chemopreventive strategies for melanoma and non-melanoma skin cancers include the ras and activator protein-1 (AP-1) signal transduction pathways. A transgenic murine melanoma model has been developed for evaluating potential agents in vivo. Agents at various stages of study include the green tea catechin epigallocatechin gallate (EGCG), the limonene derivative perillyl alcohol, the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO), selenium, retinoids and salicylates. New chemopreventive agents that can be used to complement sunscreens may result in decreased incidence, morbidity and mortality of skin cancer. Copyright (C) 2000 Elsevier Science Ltd.",
keywords = "Chemoprevention, Clinical trials, Skin neoplasms, Ultraviolet rays",
author = "Stratton, {Steven P} and Dorr, {Robert T} and Alberts, {David S}",
year = "2000",
month = "6",
doi = "10.1016/S0959-8049(00)00108-8",
language = "English (US)",
volume = "36",
pages = "1292--1297",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - The state-of-the-art in chemoprevention of skin cancer

AU - Stratton, Steven P

AU - Dorr, Robert T

AU - Alberts, David S

PY - 2000/6

Y1 - 2000/6

N2 - The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate. Our chemoprevention strategies include the development of novel agents evaluated by (1) preclinical mechanistic studies in models of ultraviolet (UV) radiation-induced skin carcinogenesis; (2) clinical studies of immunohistochemical surrogate endpoint biomarkers in high-risk patients; and (3) randomised, placebo-controlled phase I, II and III clinical chemoprevention trials. Recent clinical results validate this development model. Molecular targets of chemopreventive strategies for melanoma and non-melanoma skin cancers include the ras and activator protein-1 (AP-1) signal transduction pathways. A transgenic murine melanoma model has been developed for evaluating potential agents in vivo. Agents at various stages of study include the green tea catechin epigallocatechin gallate (EGCG), the limonene derivative perillyl alcohol, the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO), selenium, retinoids and salicylates. New chemopreventive agents that can be used to complement sunscreens may result in decreased incidence, morbidity and mortality of skin cancer. Copyright (C) 2000 Elsevier Science Ltd.

AB - The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate. Our chemoprevention strategies include the development of novel agents evaluated by (1) preclinical mechanistic studies in models of ultraviolet (UV) radiation-induced skin carcinogenesis; (2) clinical studies of immunohistochemical surrogate endpoint biomarkers in high-risk patients; and (3) randomised, placebo-controlled phase I, II and III clinical chemoprevention trials. Recent clinical results validate this development model. Molecular targets of chemopreventive strategies for melanoma and non-melanoma skin cancers include the ras and activator protein-1 (AP-1) signal transduction pathways. A transgenic murine melanoma model has been developed for evaluating potential agents in vivo. Agents at various stages of study include the green tea catechin epigallocatechin gallate (EGCG), the limonene derivative perillyl alcohol, the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO), selenium, retinoids and salicylates. New chemopreventive agents that can be used to complement sunscreens may result in decreased incidence, morbidity and mortality of skin cancer. Copyright (C) 2000 Elsevier Science Ltd.

KW - Chemoprevention

KW - Clinical trials

KW - Skin neoplasms

KW - Ultraviolet rays

UR - http://www.scopus.com/inward/record.url?scp=0034042963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034042963&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(00)00108-8

DO - 10.1016/S0959-8049(00)00108-8

M3 - Article

C2 - 10882869

AN - SCOPUS:0034042963

VL - 36

SP - 1292

EP - 1297

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -